SALT LAKE CITY, August 2, 2022 – Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the third quarter of fiscal year 2022.
- Revenues $214 million
- GAAP gross margin 34% | Non-GAAP gross margin* 35%
- GAAP operating expense $50 million | Non-GAAP operating expense* $47 million
- GAAP operating margin 11% | Non-GAAP operating margin* 13%
- GAAP net earnings $0.20 per diluted share | Non-GAAP net earnings* $0.37 per diluted share
“Our supply chain diversification efforts are beginning to show results in an otherwise challenging environment, and this enabled us to focus on meeting our customer’s needs and realize sales at the high-end of our guidance range,” said Sunny Sanyal, Chief Executive Officer of Varex. Sanyal added, “Demand remains robust and we are excited about our future growth prospects.”
Varex’s revenues of $214 million were flat sequentially, with the Medical segment down 2% and the Industrial segment up 7% from the second quarter of fiscal year 2022. Compared to the third quarter of fiscal year 2021, total revenues increased 2%, with the Medical segment flat and the Industrial segment up 8%. Non-GAAP gross margin increased to 35% in the quarter compared to 34% last quarter and non-GAAP EPS was flat sequentially at $0.37.
Balance Sheet & Cash Flow
Cash flow from operations was a use of $3 million in the third quarter of fiscal year 2022, primarily due to continued investment in inventory to support growth in the current environment. Cash, cash equivalents and marketable securities declined $5 million sequentially to $110 million at the end of the third quarter.
The following guidance is provided for the fourth quarter of fiscal year 2022:
- Revenues are expected to be between $210 million and $240 million
- Non-GAAP net earnings per diluted share is expected to be between $0.25 and $0.45
Guidance for the company’s net earnings per diluted share is provided on a non-GAAP basis only. This non-GAAP financial measure is forward-looking, and the company is unable to provide a meaningful or accurate GAAP forecast of net earnings per diluted share without unreasonable effort due to the uncertainty of amounts and timing of unusual items.
Non-GAAP Financial Measures
*Please refer to “Reconciliation between GAAP and non-GAAP Financial Measures” below for a reconciliation of non-GAAP items to the comparable GAAP measures
Conference Call Information
Varex will conduct its earnings conference call for the third quarter of fiscal year 2022 today at 3:00 p.m. Mountain Time. The conference call, including a supplemental slide presentation, will be webcast live and can be accessed at Varex’s website at vareximaging.com/news. Access will also be available by dialing 877-524-8416 from anywhere in the U.S. or by dialing 412-902-1028 from non-U.S. locations. The webcast and supplemental slide presentation will be archived on Varex’s website at vareximaging.com/quarterly-reports. A replay of the call will be available from today through August 16th at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay access code is 13731452. The listen-only webcast link is: https://event.choruscall.com/mediaframe/webcast.html?webcastid=zKtnw215
Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate Varex’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,100 people located in North America, Europe, and Asia. For more information visit vareximaging.com.
Forward Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements concerning unaudited financial results; supply chain diversification activities; industry or market outlook; customer demand and revenue trends; revenues, product volumes, or other expected future financial results or performance; and any statements using the terms “believe,” “expect,” “intend,” “outlook,” “future,” “anticipate,” “will,” “could,” “estimate,” “guidance,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varex’s actual results to differ materially from those anticipated. While forward-looking statements are based on assumptions and analyses made by us that we believe to be reasonable under the circumstances, whether actual results and developments will meet our expectations and predictions depend on a number of risks and uncertainties which could cause our actual results, performance, and financial condition to differ materially from our expectations. Such risks and uncertainties include supply chain and logistical challenges; price increases from suppliers and service providers and inflation generally; the severity and duration of the COVID-19 pandemic and its impact on both the global economy and Varex’s business; shifts in product mix; the continued impact of tariffs or a global trade war on Varex’s products and customer purchasing patterns; global economic conditions and political conditions globally or regionally, including any impact due to armed conflicts (such as the recent conflict between Russia and Ukraine as well as governmental sanctions imposed in response); demand for and delays in delivery of products of Varex or its customers; litigation costs; Varex’s ability to develop, commercialize and deploy new products; the impact of reduced or limited demand by purchasers of certain X-ray products; the impact of competitive products and pricing; and the other risks listed from time to time in our filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. Any forward-looking statements made by us in this news release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
Varex has not filed its Form 10-Q for the third quarter of fiscal year 2022. All financial results described here should be considered preliminary, and are subject to change to reflect any necessary adjustments or changes in accounting estimates, that are identified prior to the time Varex files the Form 10-Q.
For Information Contact:
Director of Investor Relations
Varex Imaging Corporation
801.973.1566 | firstname.lastname@example.org
Varex Imaging will attend the International Security Expo at Olympia London.
Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the third quarter of fiscal year 2022 following the close of regular trading on Tuesday, August 2, 2022.
Varex Imaging Corporation will attend the 2022 European Congress of Radiology (ECR) in Vienna this summer.
Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the second quarter of fiscal year 2022.
Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the second quarter of fiscal year 2022 following the close of regular trading on Tuesday, May 3, 2022.
Varex Imaging Corporation will attend the 34th annual Control international trade fair in Stuttgart, Germany
Varex Imaging Corporation today announced the partial redemption of $27 million of its 7.875% senior secured notes due 2027, which represents 10% of the outstanding principal amount of the notes.
Varex Imaging Corporation announced today that it is scheduled to present at Oppenheimer’s 32nd Annual Healthcare virtual investor conference.
Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the first quarter of fiscal year 2022.
SALT LAKE CITY, July 1, 2021 – Varex Imaging Corporation (Nasdaq: VREX) today announced the partial redemption in the amount of $30 million of its $300 million 7.875% senior secured notes due 2027, in accordance with the terms and conditions of the governing indenture
Varex Imaging Corporation today announced its unaudited financial results for the fourth quarter of fiscal year 2021.
Phoenix Convention Center for ASNT 2021 - November 15-18
Varex Imaging Corporation today announced its unaudited financial results for the third quarter of fiscal year 2021.
Varex Imaging Announces LUMEN 4336W Radiography Detector With IP68 Rating